A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson's Disease and Apathy - IRL757C003
Latest Information Update: 29 Dec 2025
At a glance
- Drugs IRL-757 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
Most Recent Events
- 29 Dec 2025 New trial record